Outcomes in patients with pancreatic and ampullary cancer whose tumors harbor pathogenic APC mutations. Utility of circulating tumor DNA (ctDNA) for the detection of minimal residual disease (MRD) ...
A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer. This is an ASCO Meeting ...
Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for therapeutics. Among them, the Y220C mutation is the ninth most frequent and it ...
Using innovative animal models and cutting-edge genomic technologies, the researchers were able to track cellular transformations in real time. Their key findings indicate that loss of TP53 gene ...
Gastric cancer (GC) ranks as the fifth-most common and fourth-deadliest cancer worldwide, presenting significant health challenges, particularly in China, where it is most prevalent and accounts for ...
GC ranks as the fifth most common and fourth deadliest cancer worldwide, presenting significant health challenges, particularly in China where it is most prevalent and accounts for nearly half of ...
Over the course of treatment, patients with relapsed/refractory acute myeloid leukemia (AML) may acquire new TP53 mutations, making ongoing monitoring for mutations crucial. “New novel therapies ...
In recent years, high-throughput technologies have provided unprecedented opportunities for analyzing cancer samples at multiple molecular levels. Each type of multi-omics dataset contributes to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results